EGFR and pancreatic neoplasm: In pancreatic cancer, silencing of galectin-3 has shown to enhance the cell surface interaction between MUC1 and EGFR in the absence of EGF stimulation and reduced the rate of endocytosis of MUC1-EGFR complex which leads to the noticeable cell surface localization of MUC1.